Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (91-100 of 383) with videos related to

Pageof 39
Sort By:
Leukemia & Lymphoma|October 30, 2009
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901John C Byrd, Bercedis L Peterson, Kanti R Rai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Gemtuzumab ozogamicin: time to resurrect?Farhad Ravandi, Elihu H Estey, Frederick R Appelbaum, et al.
Chemico-Biological Interactions|December 5, 2009
Cytogenetic and genetic pathways in therapy-related acute myeloid leukemiaZhijian Qian, John M Joslin, Thelma R Tennant, et al.
Blood|April 22, 2006
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trialsLydia Roy, Joëlle Guilhot, Tillmann Krahnke, et al.
Blood Advances|June 30, 2018
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemiaAnthony S Stein, Richard A Larson, Andre C Schuh, et al.
British Journal of Haematology|January 14, 2004
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group BMeir Wetzler, Richard K Dodge, Krzysztof Mrózek, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based reviewTheresa Hahn, Donna Wall, Bruce Camitta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Phase II trial of oral aminopterin for adults and children with refractory acute leukemiaPeter D Cole, Richard A Drachtman, Angela K Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2005
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based reviewTheresa Hahn, Donna Wall, Bruce Camitta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B studyAndreas Neubauer, Kati Maharry, Krzysztof Mrózek, et al.
Pageof 39

Showing results (91-100 of 383) with videos related to

Sort By:
Pageof 39
Leukemia & Lymphoma|October 30, 2009
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901John C Byrd, Bercedis L Peterson, Kanti R Rai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Gemtuzumab ozogamicin: time to resurrect?Farhad Ravandi, Elihu H Estey, Frederick R Appelbaum, et al.
Chemico-Biological Interactions|December 5, 2009
Cytogenetic and genetic pathways in therapy-related acute myeloid leukemiaZhijian Qian, John M Joslin, Thelma R Tennant, et al.
Blood|April 22, 2006
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trialsLydia Roy, Joëlle Guilhot, Tillmann Krahnke, et al.
Blood Advances|June 30, 2018
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemiaAnthony S Stein, Richard A Larson, Andre C Schuh, et al.
British Journal of Haematology|January 14, 2004
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group BMeir Wetzler, Richard K Dodge, Krzysztof Mrózek, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based reviewTheresa Hahn, Donna Wall, Bruce Camitta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Phase II trial of oral aminopterin for adults and children with refractory acute leukemiaPeter D Cole, Richard A Drachtman, Angela K Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2005
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based reviewTheresa Hahn, Donna Wall, Bruce Camitta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B studyAndreas Neubauer, Kati Maharry, Krzysztof Mrózek, et al.
Pageof 39